Merrimack Pharma (MACK) Tops Q1 EPS by 5c
Tweet
Share
E-mailGet Alerts MACK Hot Sheet
Join SI Premium – FREE
Merrimack Pharma (NASDAQ: MACK) reported Q1 EPS of ($0.33), $0.05 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $21.3 million versus the consensus estimate of $24.16 million.
For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Byline Bancorp (BY) Tops Q1 EPS by 6c
- Utah Medical Products (UTMD) Reports Q1 EPS of $1.10
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
